Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE Study: Adalimumab With Reduced vs Maximum-Tolerated Methotrexate in Early RA
jRCT1031180088Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised trial of adalimumab in rheumatoid arthritis (RA) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: SDAI remission rate at Week 48. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT1031180088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031180088.